Clinical Trial

A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors

Terminated Phase 1/2
View on ClinicalTrials.gov →
Why the trial stopped
Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial.
Summary
This is an open-label, non-randomized, Phase 1b/2 study to determine the safety and tolerability of NC410 when combined with a standard dose of pembrolizumab. This study will also assess the clinical benefit of combination therapy in participants with advanced unresectable and/or metastatic ICI refractory solid tumors OR ICI naïve MSS/MSI-low solid tumors
Protocol Amendment History 5 changes
critical Trial terminated 2026-08-14
critical Trial terminated: Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial. 2026-08-14
critical Primary endpoint(s) modified 2026-08-14
notable Primary completion moved earlier: 2025-07 -> 2025-04-30 2026-08-14
minor Completion moved earlier: 2025-11 -> 2025-04-30 2026-08-14
Trial Details
NCT Number NCT05572684
Lead Sponsor NextCure, Inc.
Collaborators: Merck Sharp & Dohme LLC
Conditions Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer, Esophageal Cancer +4 more
Enrollment 97 participants
Start Date 2022-10-06
Primary Completion 2025-04-30 (estimated)
Study Completion 2025-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-13